This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Nandrolone is an anabolic steroid indicated to increase bone density and muscle mass in patients with osteoporosis.
- Generic Name
- Nandrolone
- DrugBank Accession Number
- DB13169
- Background
Nandrolone, also known as 19-nortestosterone or 19-norandrostenolone, is a synthetic anabolic-androgenic steroid (AAS) derived from testosterone.
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Nandrolone (DB13169)
- Weight
- Average: 274.3978
Monoisotopic: 274.193280076 - Chemical Formula
- C18H26O2
- Synonyms
- (17β)-17-hydroxyestr-4-en-3-one
- 19-norandrostenolone
- 19-nortestosterone
- Nandrolona
- Nandrolone
- Nandrolonum
- External IDs
- NSC-3351
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose Nandrolone may increase the hypoglycemic activities of Acarbose. Acenocoumarol Nandrolone may increase the anticoagulant activities of Acenocoumarol. Acetohexamide Nandrolone may increase the hypoglycemic activities of Acetohexamide. Albiglutide Nandrolone may increase the hypoglycemic activities of Albiglutide. Allantoin The therapeutic efficacy of Allantoin can be increased when used in combination with Nandrolone. Alogliptin Nandrolone may increase the hypoglycemic activities of Alogliptin. Beclomethasone dipropionate The risk or severity of edema formation can be increased when Nandrolone is combined with Beclomethasone dipropionate. Betamethasone The risk or severity of edema formation can be increased when Nandrolone is combined with Betamethasone. Betamethasone phosphate The risk or severity of edema formation can be increased when Nandrolone is combined with Betamethasone phosphate. Bromocriptine Nandrolone may increase the hypoglycemic activities of Bromocriptine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Menidrabol
Categories
- ATC Codes
- S01XA11 — Nandrolone
- S01XA — Other ophthalmologicals
- S01X — OTHER OPHTHALMOLOGICALS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- Drug Categories
- Alimentary Tract and Metabolism
- Anabolic Agents
- Anabolic Agents for Systemic Use
- Anabolic Steroids
- Androgens
- Estranes
- Estren Derivatives
- Estrenes
- Fused-Ring Compounds
- Gonadal Hormones
- Gonadal Steroid Hormones
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Nandrolone and esters
- Ophthalmologicals
- Sensory Organs
- Steroids
- Testosterone Congeners
- Thyroxine-binding globulin inhibitors
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Estrane steroids
- Direct Parent
- Estrogens and derivatives
- Alternative Parents
- 3-oxo delta-4-steroids / 17-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Secondary alcohols / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- 17-hydroxysteroid / 3-oxo-delta-4-steroid / 3-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Carbonyl group / Cyclic alcohol / Cyclic ketone / Cyclohexenone / Delta-4-steroid
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 3-oxo Delta(4)-steroid, 17beta-hydroxy steroid, anabolic androgenic steroid (CHEBI:7466) / Estrane and derivatives (C07254) / C18 steroids (estrogens) and derivatives (LMST02010044)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6PG9VR430D
- CAS number
- 434-22-0
- InChI Key
- NPAGDVCDWIYMMC-IZPLOLCNSA-N
- InChI
- InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1
- IUPAC Name
- (1S,3aS,3bR,9aR,9bS,11aS)-1-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
- SMILES
- [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0002725
- KEGG Compound
- C07254
- PubChem Compound
- 9904
- PubChem Substance
- 347829275
- ChemSpider
- 9520
- BindingDB
- 50080092
- 7244
- ChEBI
- 7466
- ChEMBL
- CHEMBL757
- ZINC
- ZINC000003814379
- PharmGKB
- PA164746281
- PDBe Ligand
- 6VW
- Wikipedia
- Nandrolone
- PDB Entries
- 5kp4
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Aplastic Anemia / Blood Diseases / Hematologic Disease and Disorders / Pancytopenia 1 2 Terminated Treatment Critically Ill Patients / Malnutrition 1 2, 3 Completed Treatment Burns 1 2, 3 Terminated Treatment Burns 1 Not Available Completed Supportive Care Cancer Cachexia 1 Not Available Completed Treatment Muscular Disorders, Atrophic 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0561 mg/mL ALOGPS logP 2.6 ALOGPS logP 3.07 Chemaxon logS -3.7 ALOGPS pKa (Strongest Acidic) 18.25 Chemaxon pKa (Strongest Basic) -0.88 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 37.3 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 79.95 m3·mol-1 Chemaxon Polarizability 32.27 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created at February 15, 2017 19:13 / Updated at June 05, 2021 09:12